Products & Services · Indefinite-lived intangible assets, period increase (decrease)
Tukysa — Indefinite-lived intangible assets, period increase (decrease)
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2026
Last reportedQ1 2026
How to read this metric
An increase typically reflects strategic investment or acquisition of rights, while a decrease often signals impairment charges or asset write-downs.
Detailed definition
This metric tracks the net change in the carrying value of indefinite-lived intangible assets specifically associated wi...
Peer comparison
Comparable to IPR&D or brand asset adjustments reported by other pharmaceutical companies following M&A activity.
Metric ID:
pfe_segment_tukysa_indefinite_lived_intangible_assets_period_increase_decreaseHistorical Data
1 periods
| Q1 '26 | |
|---|---|
| Value | -$580.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's tukysa — indefinite-lived intangible assets, period increase (decrease)?
- Pfizer (PFE) reported tukysa — indefinite-lived intangible assets, period increase (decrease) of -$580.00M in Q1 2026.
- What does tukysa — indefinite-lived intangible assets, period increase (decrease) mean?
- The net change in the value of non-amortizing intangible assets linked to the Tukysa product line.